Ratings InfuSystem Holdings, Inc.

Equities

INFU

US45685K1025

Market Closed - Nyse 04:00:00 2024-05-28 pm EDT 5-day change 1st Jan Change
7.51 USD +5.03% Intraday chart for InfuSystem Holdings, Inc. +13.27% -28.75%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 63.09 times its estimated earnings per share for the ongoing year.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
-28.75% 152M
C-
-7.38% 181B
C+
-0.46% 108B
C
-6.98% 66.12B
A
+2.65% 50.65B
B-
+5.27% 43.11B
B-
+6.01% 40.74B
B+
+19.92% 31.6B
B
+15.75% 25.56B
A-
-7.00% 24.16B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. INFU Stock
  4. Ratings InfuSystem Holdings, Inc.